In a phase I clinical trial, which combined adoptive T cell therapy with intralesional administration of adenovirus expressing IFN-γ in metastatic melanoma, 38.5% of the patients had an overall objective response and 46% were able to control the disease (245). This evidence concerns the gene IFNG and metastatic melanoma.